Related references
Note: Only part of the references are listed.Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors
Patrick T. Ebbert et al.
HAEMOPHILIA (2020)
Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort
Assaf A. Barg et al.
PEDIATRIC BLOOD & CANCER (2019)
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
Steven W. Pipe et al.
LANCET HAEMATOLOGY (2019)
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
Guy Young et al.
BLOOD (2019)
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
J. Mahlangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
Peter J. Lenting et al.
BLOOD (2017)
Validation of a New Pediatric Joint Scoring System From the International Hemophilia Prophylaxis Study Group: Validity of the Hemophilia Joint Health Score
Brian M. Feldman et al.
ARTHRITIS CARE & RESEARCH (2011)
Mild hemophilia A
M. Franchini et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Share Paper
